Literature DB >> 31209181

Glutaminase Activity of L-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia.

Wai-Kin Chan1, Thomas D Horvath1, Lin Tan1, Todd Link2, Karine G Harutyunyan3, Michael A Pontikos1, Andriy Anishkin4, Di Du1, Leona A Martin1, Eric Yin1, Susan B Rempe5, Sergei Sukharev4, Marina Konopleva3, John N Weinstein1, Philip L Lorenzi6.   

Abstract

We and others have reported that the anticancer activity of L-asparaginase (ASNase) against asparagine synthetase (ASNS)-positive cell types requires ASNase glutaminase activity, whereas anticancer activity against ASNS-negative cell types does not. Here, we attempted to disentangle the relationship between asparagine metabolism, glutamine metabolism, and downstream pathways that modulate cell viability by testing the hypothesis that ASNase anticancer activity is based on asparagine depletion rather than glutamine depletion per se. We tested ASNase wild-type (ASNaseWT) and its glutaminase-deficient Q59L mutant (ASNaseQ59L) and found that ASNase glutaminase activity contributed to durable anticancer activity against xenografts of the ASNS-negative Sup-B15 leukemia cell line in NOD/SCID gamma mice, whereas asparaginase activity alone yielded a mere growth delay. Our findings suggest that ASNase glutaminase activity is necessary for durable, single-agent anticancer activity in vivo, even against ASNS-negative cancer types. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31209181      PMCID: PMC6726508          DOI: 10.1158/1535-7163.MCT-18-1329

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  17 in total

1.  The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.

Authors:  Wai Kin Chan; Philip L Lorenzi; Andriy Anishkin; Preeti Purwaha; David M Rogers; Sergei Sukharev; Susan B Rempe; John N Weinstein
Journal:  Blood       Date:  2014-03-21       Impact factor: 22.113

2.  Mechanism of sensitivity of cultured pancreatic carcinoma to asparaginase.

Authors:  M C Wu; G K Arimura; A A Yunis
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

3.  Catalytic Role of the Substrate Defines Specificity of Therapeutic l-Asparaginase.

Authors:  Andriy Anishkin; Juan M Vanegas; David M Rogers; Philip L Lorenzi; Wai Kin Chan; Preeti Purwaha; John N Weinstein; Sergei Sukharev; Susan B Rempe
Journal:  J Mol Biol       Date:  2015-07-02       Impact factor: 5.469

Review 4.  Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.

Authors:  Vassilios I Avramis; Eduard H Panosyan
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.

Authors:  Shotaro Iwamoto; Keichiro Mihara; James R Downing; Ching-Hon Pui; Dario Campana
Journal:  J Clin Invest       Date:  2007-03-22       Impact factor: 14.808

6.  Epigenetic changes in the repression and induction of asparagine synthetase in human leukemic cell lines.

Authors:  Y Ding; Z Li; J D Broome
Journal:  Leukemia       Date:  2005-03       Impact factor: 11.528

Review 7.  Asparaginases: biochemical pharmacology and modes of drug resistance.

Authors:  Vassilios I Avramis
Journal:  Anticancer Res       Date:  2012-07       Impact factor: 2.480

8.  Adverse effects of pegaspargase in pediatric patients receiving doses greater than 3,750 IU.

Authors:  Rachel Lebovic; Natalie Pearce; Laura Lacey; James Xenakis; Cassidy B Faircloth; Patrick Thompson
Journal:  Pediatr Blood Cancer       Date:  2017-04-24       Impact factor: 3.167

9.  No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.

Authors:  Wing H Tong; Rob Pieters; Wim C J Hop; Claudia Lanvers-Kaminsky; Joachim Boos; Inge M van der Sluis
Journal:  Pediatr Blood Cancer       Date:  2012-09-07       Impact factor: 3.167

10.  Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.

Authors:  Barbara Szymanska; Urszula Wilczynska-Kalak; Min H Kang; Natalia L M Liem; Hernan Carol; Ingrid Boehm; Daniel Groepper; C Patrick Reynolds; Clinton F Stewart; Richard B Lock
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

View more
  20 in total

1.  Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.

Authors:  Natalia Baran; Alessia Lodi; Yogesh Dhungana; Shelley Herbrich; Meghan Collins; Shannon Sweeney; Renu Pandey; Anna Skwarska; Shraddha Patel; Mathieu Tremblay; Vinitha Mary Kuruvilla; Antonio Cavazos; Mecit Kaplan; Marc O Warmoes; Diogo Troggian Veiga; Ken Furudate; Shanti Rojas-Sutterin; Andre Haman; Yves Gareau; Anne Marinier; Helen Ma; Karine Harutyunyan; May Daher; Luciana Melo Garcia; Gheath Al-Atrash; Sujan Piya; Vivian Ruvolo; Wentao Yang; Sriram Saravanan Shanmugavelandy; Ningping Feng; Jason Gay; Di Du; Jun J Yang; Fieke W Hoff; Marcin Kaminski; Katarzyna Tomczak; R Eric Davis; Daniel Herranz; Adolfo Ferrando; Elias J Jabbour; M Emilia Di Francesco; David T Teachey; Terzah M Horton; Steven Kornblau; Katayoun Rezvani; Guy Sauvageau; Mihai Gagea; Michael Andreeff; Koichi Takahashi; Joseph R Marszalek; Philip L Lorenzi; Jiyang Yu; Stefano Tiziani; Trang Hoang; Marina Konopleva
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

2.  ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase.

Authors:  Robert T Williams; Rohiverth Guarecuco; Leah A Gates; Douglas Barrows; Maria C Passarelli; Bryce Carey; Lou Baudrier; Swarna Jeewajee; Konnor La; Benjamin Prizer; Sohail Malik; Javier Garcia-Bermudez; Xiphias Ge Zhu; Jason Cantor; Henrik Molina; Thomas Carroll; Robert G Roeder; Omar Abdel-Wahab; C David Allis; Kıvanç Birsoy
Journal:  Cell Metab       Date:  2020-04-07       Impact factor: 27.287

Review 3.  Methionine metabolism in health and cancer: a nexus of diet and precision medicine.

Authors:  Sydney M Sanderson; Xia Gao; Ziwei Dai; Jason W Locasale
Journal:  Nat Rev Cancer       Date:  2019-09-12       Impact factor: 60.716

Review 4.  Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy.

Authors:  Wen-Hsuan Yang; Yijian Qiu; Olivia Stamatatos; Tobias Janowitz; Michael J Lukey
Journal:  Trends Cancer       Date:  2021-05-18

5.  Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia.

Authors:  Manjunath Nookala Krishnamurthy; Gaurav Narula; Khushboo Gandhi; Ankita Awase; Ruta Pandit; Sunil Raut; Ritu Singh; Vikram Gota; Shripad Dinanath Banavali
Journal:  JCO Glob Oncol       Date:  2020-07

Review 6.  Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia.

Authors:  Martina Chiu; Giuseppe Taurino; Massimiliano G Bianchi; Michael S Kilberg; Ovidio Bussolati
Journal:  Front Oncol       Date:  2020-01-09       Impact factor: 6.244

Review 7.  Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias.

Authors:  Aboli Bhingarkar; Hima V Vangapandu; Sanjay Rathod; Keito Hoshitsuki; Christian A Fernandez
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

8.  Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway.

Authors:  Bingbing Dai; Jithesh J Augustine; Ya'an Kang; David Roife; Xinqun Li; Jenying Deng; Lin Tan; Leona A Rusling; John N Weinstein; Philip L Lorenzi; Michael P Kim; Jason B Fleming
Journal:  Cell Death Dis       Date:  2021-07-10       Impact factor: 8.469

Review 9.  Asparagine: A Metabolite to Be Targeted in Cancers.

Authors:  Jie Jiang; Sandeep Batra; Ji Zhang
Journal:  Metabolites       Date:  2021-06-19

10.  Improving the Treatment of Acute Lymphoblastic Leukemia.

Authors:  Ashish Radadiya; Wen Zhu; Adriana Coricello; Stefano Alcaro; Nigel G J Richards
Journal:  Biochemistry       Date:  2020-08-23       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.